SG Americas Securities LLC Has $758,000 Stock Holdings in McKesson Co. (NYSE:MCK)

SG Americas Securities LLC reduced its stake in shares of McKesson Co. (NYSE:MCK - Free Report) by 98.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,330 shares of the company's stock after selling 79,764 shares during the quarter. SG Americas Securities LLC's holdings in McKesson were worth $758,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Wolff Wiese Magana LLC grew its stake in McKesson by 742.9% in the third quarter. Wolff Wiese Magana LLC now owns 59 shares of the company's stock valued at $29,000 after acquiring an additional 52 shares during the period. MidAtlantic Capital Management Inc. acquired a new position in shares of McKesson in the 3rd quarter valued at approximately $29,000. RPg Family Wealth Advisory LLC bought a new stake in McKesson during the 3rd quarter worth approximately $31,000. ORG Wealth Partners LLC acquired a new stake in McKesson during the 3rd quarter worth approximately $40,000. Finally, Bruce G. Allen Investments LLC lifted its stake in McKesson by 51.9% in the fourth quarter. Bruce G. Allen Investments LLC now owns 82 shares of the company's stock valued at $47,000 after buying an additional 28 shares in the last quarter. 85.07% of the stock is owned by institutional investors.

McKesson Stock Performance

McKesson stock traded up $1.98 during midday trading on Thursday, reaching $605.16. 473,344 shares of the company's stock were exchanged, compared to its average volume of 655,286. The stock's 50-day simple moving average is $591.81 and its 200 day simple moving average is $561.82. The firm has a market cap of $76.82 billion, a price-to-earnings ratio of 31.34, a P/E/G ratio of 1.26 and a beta of 0.52. McKesson Co. has a 52 week low of $464.42 and a 52 week high of $637.51.

McKesson (NYSE:MCK - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported $7.07 earnings per share for the quarter, topping analysts' consensus estimates of $6.88 by $0.19. McKesson had a negative return on equity of 207.50% and a net margin of 0.77%. The business had revenue of $93.65 billion for the quarter, compared to analyst estimates of $89.33 billion. During the same period in the previous year, the firm earned $6.23 EPS. The firm's revenue was up 21.3% compared to the same quarter last year. Research analysts forecast that McKesson Co. will post 32.73 earnings per share for the current year.

McKesson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 1st. Shareholders of record on Monday, March 3rd will be given a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a yield of 0.47%. McKesson's dividend payout ratio (DPR) is presently 14.71%.

Insider Transactions at McKesson

In other news, EVP Leann B. Smith sold 579 shares of the business's stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $572.79, for a total value of $331,645.41. Following the completion of the sale, the executive vice president now owns 864 shares of the company's stock, valued at approximately $494,890.56. The trade was a 40.12 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.11% of the company's stock.

Wall Street Analysts Forecast Growth

MCK has been the topic of several research reports. Citigroup cut their price objective on shares of McKesson from $713.00 to $677.00 and set a "buy" rating on the stock in a research report on Friday, January 10th. StockNews.com raised McKesson from a "hold" rating to a "buy" rating in a research report on Wednesday, November 6th. Baird R W raised McKesson from a "hold" rating to a "strong-buy" rating in a research report on Thursday, November 7th. Robert W. Baird raised McKesson from a "neutral" rating to an "outperform" rating and upped their price target for the stock from $531.00 to $688.00 in a research report on Thursday, November 7th. Finally, Leerink Partners lowered their price objective on shares of McKesson from $665.00 to $630.00 and set an "outperform" rating on the stock in a report on Monday, October 7th. Two analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, McKesson currently has a consensus rating of "Moderate Buy" and an average target price of $646.14.

McKesson Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.